MET-Driven Kidney Cancer: Combination of Durvalumab and Savolitinib Under Study
Posted: Wednesday, August 4, 2021
A study conducted by Cristina Suárez Rodriguez, MD, of Vall d’ Hebron University Hospital, Barcelona, and colleagues found that the combination of the MET inhibitor savolitinib and the PD-L1 inhibitor durvalumab demonstrates clinical activity in patients with MET-driven metastatic papillary renal cancer. The efficacy of this combination was evaluated, with a phase III randomized study planned, and their results were presented during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 4511).
This single-arm, phase I/II trial focused on 42 patients with MET-driven metastatic papillary renal cancer. Participants were administered 1,500 mg of durvalumab every 4 weeks and 600 mg of savolitinib daily. MET DNA alterations were defined as MET kinase domain mutations, MET or HGF amplification, or chromosome 7 gain.
Of the total participants, 41 underwent treatment, with a median follow-up of 26.8 months. The confirmed response rate was 29%, and the median progression-free survival was 4.9 months. Among the cohort, 14 patients had MET-driven disease, with 10 having received no previous systemic therapy; one patient had PD-L1–positive disease.
According to the International Metastatic Renal Cell Carcinoma Database Consortium, eight patients with MET-driven tumors had intermediate-risk disease, five had good-risk disease, and one had poor-risk disease. The confirmed response rate was 57%, with a duration of response of 9.4 months. The median overall survival and progression-free survival for these participants were 27.4 months and 9.4 months, respectively, and no new safety signals were observed.
Disclosure: For full disclosures of the study authors, visit coi.asco.org.